Effect of suplatast tosilate on airway hyperresponsiveness and inflammation in asthma patients

M. Yoshida, H. Aizawa, H. Inoue, K. Matsumoto, H. Koto, M. Komori, S. Fukuyama, M. Okamoto, N. Hara

研究成果: ジャーナルへの寄稿学術誌査読

21 被引用数 (Scopus)


Because eosinophilic airway inflammation is a characteristic of bronchial asthma, the treatment of such inflammation is important in the management of this disease. Suplatast tosilate is a novel anti-asthma drug that supresses eosinophil proliferation and infiltration through selective inhibition of Th2 cytokine synthesis. We investigated the effect of oral suplatast tosilate therapy in patients with mild and moderate asthma. Twenty-eight asthma patients were randomized into two groups with or without suplatast tosilate treatment (100 mg t.i.d. for 28 days). We examined the blood eosinophil counts, eosinophilic cationic protein level, sputum eosinophil count, exhaled nitric oxide level, and airway responsiveness before and after treatment. In patients treated with suplatast tosilate, the eosinophil count in the blood and sputum was significantly decreased after treatment, while there was no such change in the patients without suplatast treatment. The exhaled nitric oxide level and airway responsiveness (measured using an Astograph) were also decreased after treatment with suplatast tosilate, while there were no significant changes in patients without suplatast tosilate. These results strongly suggest that oral administration of suplatast tosilate suppresses airway hyperresponsiveness in asthma patients by reducing eosinophilic inflammation in the airways.

ジャーナルJournal of Asthma
出版ステータス出版済み - 2002

!!!All Science Journal Classification (ASJC) codes

  • 小児科学、周産期医学および子どもの健康
  • 免疫アレルギー学
  • 呼吸器内科


「Effect of suplatast tosilate on airway hyperresponsiveness and inflammation in asthma patients」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。